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Criteria for pathogenicityselection that occurs during embryonic development, the particular location and
features of mitochondrial DNA make it especially susceptible to accumulating point mutations, giving rise to
a large number of mitochondrial DNA variants. Many of these will have moderate or no phenotypic effects
but others will be the cause of very dramatic diseases, usually known as mitochondriopathies. Because of the
abundance of different mitochondrial DNA variants, it is not easy to determine whether a new mutation is
pathogenic. To facilitate this task, different criteria have been proposed, but they are often either too severely
or too loosely applied. Citing examples from the literature, in this paper we discuss some critical aspects of
these criteria.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The ﬁrst discoveries that open a new scientiﬁc ﬁeld are usually the
most obvious and they determine the bases of a new area of research.
However, as the knowledge of the new ﬁeld of research advances, the
new ﬁndings defy the previous conceptions. Thus, very useful criteria
have been proposed in the ﬁeld of mitochondrial DNA (mtDNA)
diseases [1–3] (Table 1), to decide whether a newly found point
mutation in this genome is pathogenic and, therefore, if it is the cause
of a disease. Nevertheless, there are many exceptions to the rule, and
this makes it essential that we should be extremely careful in the
application of these criteria and maintains an open mind in deﬁning
the pathogenicity of a new mutation, in order to progress in this ﬁeld.
In this paperwe hope to create a general overview of these criteria and
to discuss several examples found in the literature that will yield some
clues on how to apply these criteria.
2. Mitochondria are unpopulated suburbs
Eukaryotic cells derive from an event of endosymbiosis. One of the
organisms that participated in this endosymbiosis, the one that gave
rise to mitochondria, was similar to an alpha-proteobacterium. Some
of the genes contained in these protomitochondria, the redundanta, Biología Molecular y Celular,
761640; fax: +34 976761612.
ll rights reserved.ones, were removed, and many others migrated to the nucleus. Thus,
the DNA that remained in the mitochondria is much smaller than the
bacterial genome [4]. There are several reasons for this reduction in
size. The migration of the mitochondrial genes to the nucleus could
represent an important evolutionary advantage due to the possibility
of recombination. However, this does not explain why, in the mtDNA,
there are almost no non-coding nucleotides between the different
genes, and no introns within the genes, or why some of the genes
overlap and several stop codons are not encoded in the mtDNA and
have to be originated after polyadenylation of their corresponding
mRNAs. Moreover, mtDNA-encoded genes are smaller than those
encoded in the nuclear DNA (nDNA) or in bacteria [4]. A very extreme
situation is found in the mitochondrial ribosomes. Bacterial and
cytosolic ribosomes have a 2/1 ratio in the rRNA/protein proportion
but this ratio is reversed—1/2—for the mitochondrial ribosomes. Very
long segments of the MT-RNR genes have disappeared and their
functions have been taken over by new proteins encoded in the
nuclear chromosomes [5]. Thus, we might conclude that most of the
neighbors in the suburbs died or moved downtown and that this is
still happening, giving rise to many mitochondrial pseudogenes or
numts [6]. The remaining genes decreased their size and removed
every unessential nucleotide, providing an example of genetic
economy. A possible explanation for the permanence of a genetic
system within the mitochondria is that these genes are required for
the correct functioning of the organelle, offering the quickest, ﬁnest
and most local regulation [7], or because this allows the co-evolution
of genes involved in the same function [8].
Table 1
Pathogenicity criteria for mtDNA point mutations
⁎ The mutation must be present in patients and absent in controls.
⁎ The mutation must be found in different mitochondrial genetic backgrounds.
⁎ The mutation must be the best mtDNA candidate variant to be pathologic.
⁎ The percentage of the mutation must correlate with the phenotype.
⁎ The mutation must affect highly evolutionary conserved nucleotides.
⁎ The mutation must affect functionally important domains.
⁎ The transference of the mutated mtDNA to another cell line must be accompanied by
the transference of the cell or molecular defect.
Table 2
Mitochondrial DNA mutations frequently associated to speciﬁc phenotypes
Phenotype Mutation Gene
LHON m.3460GNA MT-ND1
m.11778GNA MT-ND4
m.14484TNC MT-ND6
Leigh (MILS)/NARP m.8993TNG MT-ATP6
MELAS/diabetes m.3243ANG MT-TL1
MERRF m.8344ANG MT-TK
Non-syndromic deafness m.1555ANG MT-RNR1
MITOMAP: A HumanMitochondrial Genome Database, 2005. http://www.mitomap.org.
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lineage. Mitochondria from spermatozoa penetrate to the ovum but
they are selectively marked with ubiquitin and apparently removed
[9]. It has been recently found that even before the elimination of the
spermatozoa mitochondria, themtDNA is degraded [10]. Spermatozoa
are germinal cells but the behavior of their mitochondria is similar to
that of somatic cells. They are very active [11] and produce many
mutagenic reactive oxygen species (ROS). Thus, by removing the
paternal mtDNA, the possibility of transmitting mtDNA mutations
decreases enormously. In fact, the only known human paternal
contribution to the next generation is associated with a pathologic
mutation in the mtDNA [12].
All these observations suggest that staying in the mitochondria, for
most genes, was not evolutionarily advantageous.
3. Why are these suburbs so hostile?
mtDNA is located in the mitochondrial matrix close to the inner
membrane where the electron transport chain (ETC) is embedded.
The ETC is the main source of ROS in the cell and these compounds
promote mutations in the mtDNA. In recognizing the importance of
ROS for the cell, we must also note that some antioxidant enzymes
necessary for the elimination of ROS, such as superoxide dismutase
and catalase, are catalytically perfect, meaning their limiting factor is
not the velocity of the enzyme but the chance to ﬁnd the substrate
[13]. The mutational process induced by ROS is facilitated because
this genome is not covered with histones, although there are other
proteins such as mtTFA organizing mitochondrial nucleoids. More-
over, mtDNA can replicate more than once in the cell cycle and,
during replication, long segments of mtDNA may remain as single
strands, allowing the formation of secondary structures that may
hamper the progress of the DNA polymerase and promote the
appearance of new mtDNA mutations. Conversely, the repair systems
for mtDNA are not as abundant as those for nDNA [14]. For all these
reasons, mtDNA may accumulate mutations at a higher rate than
nDNA. Interspeciﬁc comparisons suggest that mtDNA may ﬁx
mutations 5 to 10 times faster than nDNA genes [15] but intraspeciﬁc
comparisons have found even higher mutational rates. Furthermore,
pedigree analysis has found rates 10 times higher than in the
phylogenetic studies [16].
Since 92.7% of the mtDNA sequence encodes genes, most of the
mutations in this genomewill affect anmtDNA gene. Further, the non-
coding segments contain regulatory sequences for replication and
transcription and, very likely, mutations in these regions will also have
phenotypic effects [17].
4. Frequent mtDNA pathologic point mutations
The frequency of mtDNA diseases is high. It has been estimated
that one out of approximately 8000 individuals harbors a pathogenic
mtDNA mutation [18]. However, only a few mtDNA pathologic point
mutations account for the majority of cases (Table 2). Thus, the
m.3243ANG andm.8344ANGmutations are at least twice as prevalent
as all the other mtDNA point mutations known to cause disorders
involving the central nervous system [19]. Moreover, only around halfof theMT-ND andMT-ATPmutations have been reported in more than
one pedigree, and practically all theMT-CYB andMT-COmutations are
unique to one patient or one family [20].
Why are these seven mutations of Table 2 so frequently found in
comparisonwith other pathologicmutations [21]. One possibility is an
evaluation bias since thesemutations were among the ﬁrst discovered
and it is quite possible that they have been more frequently checked
for. However, many other pathologic mutations reported during those
years have rarely been found again. For example, the m.14459GNA
LHON mutation was reported in 1994 [22]. Since then, we have
checked this transition in 373 patients, negative for the most common
mutations and suspected of suffering LHON, and none of them had
this mutation. Another possibility is that scientiﬁc journals are not
interested anymore in already-reported mtDNA mutations. However,
the ﬁrst pathologic point mutation to be described [23] and many
other common mtDNA mutations continue being reported nowadays.
An interesting common feature of these mutations is that they are
usually associated with very well-deﬁned phenotypes, although some
particular mtDNA mutations are associated with very different
phenotypes. In contrast, there are other pathologic mutations always
reported in associationwith the same phenotype, such as the deafness
mutation m.1494CNT, and they are not so frequent in the patient
population. Another possible explanation for the high frequency of the
common mutations is that they could be located in mtDNA regions
with special sequence features. However, apparently only two of these
six mutations (m.1555ANG, m.3243ANG) are located in genes with
important secondary structures that could affect the DNA polymerase
activity and increase the mutational rate. Moreover, there are no
particular characteristic sequences around these six nucleotide
positions, and single nucleotide polymorphisms (SNPs) are not
frequently found in the 20 nucleotides around these pathologic
positions. Another possible reason is that these mutations are not very
pathologic and they survive more frequently the negative selection
during embryonic development. Some of them present incomplete
penetrance and they require the action of other factors to cause
disease. For example, for some of the LHON mutations, the
mitochondrial haplogroup (group of phylogenetically related mtDNA
genotypes) strongly inﬂuences the chances of developing the disease
[24]. In other cases, such as the deafness m.1555ANG mutation,
environmental factors like antibiotics increase pathogenicity [25]. Still
others, such as the MILS mutation, need to be in a high percentage of
heteroplasmy to produce the disorder [26]. Mutations would be
expected to occur randomly in mtDNA and many of them should be
very pathologic. In fact, mutations provoking stop codons have been
found very frequently in colonic crypt stem cells [27]. Thus, it is
probable that mutations in other nucleotides suffer a strong negative
selection, as has been recently shown [28–30]. However, other
apparently less dramatic mutations, such as the previous mentioned
m.1494CNT, are not very prevalent. Therefore, a combination of these
and other possible reasons will probably be responsible for the
relatively high frequency of the most common mtDNA pathologic
point mutations.
The important fact is that, although the discovery of the same
mutation in more than one pedigree and always associated to a
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city, as we have previously mentioned, it is really extremely rare to
ﬁnd the same new pathologic mutation in more than one pedigree.
5. New mtDNA pathologic point mutations
Where should we look for new mutations when a frequent
mtDNA pathologic point mutation is not responsible for mitochon-
drial disease? It is not unusual in mitochondrial pathology that the
same phenotype is associated with very different mutations. For
example, many genetic variants have been associated with Leigh
Syndrome (LS), such as mutations in MT-ATP6 or in other mtDNA-
encoded proteins or tRNA genes (www.mitomap.org). Nuclear
mutations in structural proteins from several ETC complexes,
mutations in OXPHOS complex assembly proteins, and even muta-
tions in proteins not directly related with the OXPHOS system have
also been associated with LS [31]. Thus, clinical data, except for very
particular phenotypes, are not very useful to pinpoint a speciﬁc
mtDNA gene as the cause of a disease. The subsarcolemmal
accumulation of mitochondria and the presence of red ragged ﬁbers
(RRF) are frequently found associated with mtDNA depletion [32]
and deletions, or mt-tRNA mutations [33], and they are occasionally
found in other mitochondrial diseases caused by pathologic point
mutations in mtDNA-encoded protein genes. Thus, histochemical
data are not very useful in helping to select an mtDNA gene to
examine for pathologic mutations. Usually, the respiratory complex
activities can give some clues about the location of the pathologic
mutation. Mutations in mt-tRNAs will produce multi-enzymatic
defects, and mutations in mtDNA-encoded protein genes should
cause isolated enzymatic defects. However, some mutations in
mtDNA-encoded protein genes cause multi-enzymatic defects [34],
probably because they increase ROS production and cause a
secondary effect on other complexes or because they are necessary
to stabilize the supercomplexes [35]. Thus, biochemical activities are
not sufﬁcient indicators to target an mtDNA gene. Probably, then, the
only way to ﬁnd a pathologic mutation is to sequence the whole
mtDNA.
New mutations in coding genes may be good candidates to be
pathologic, but we cannot rule out a new mutation in a non-coding
nucleotide as the cause of the diseasewithout a second thought [36]. It
is curious that, as previously mentioned, large portions of the mt-
rRNAs have disappeared duringmtDNA evolution yet some small non-
coding segments are still part of the mtDNA. Some of these non-
coding mutations might affect RNA processing [37]. Mutations in
segments of the control region without a deﬁned function might also
be important. There are sequences in the control region that are better
conserved than sequences in some protein genes [38]. Moreover, other
apparently non-pathologic mutations, such as synonymous changes
affecting the stability of the mRNAs [39] or mitochondrial HREs, could
also have phenotypic effects by altering the binding of transcription
factors, as already shown for nuclear HREs [40]. Therefore, we need to
be more cautious when ruling out these changes as possibly
pathologic mutations [41].
The discovery of a good candidate pathologic mutation in the
mtDNA does not preclude the need to resequence the whole mtDNA.
In 1997, a pathologic mutation associated with acute rhabdomyolysis
was reported in the mtDNA MT-TF gene encoding tRNAPhe [42].
However, the complete sequencing of mtDNA some years later
showed that the true pathogenic mutation was a novel mutation in
the cytochrome oxidase subunit II gene [43]. These two studies by the
same group, one of the teams with more experience in the
mitochondrial pathology ﬁeld, demonstrate the importance of
whole mitochondrial genome sequencing. But does ﬁnding a better
candidate mutation rule out the pathogenicity of the previous one?
Them.606ANG/MT-TFmutation has been described four times, two of
them in different haplogroups of control populations [44,45], and theother two times associated with patients suspected of suffering a
mitochondrial disease [43]. The nucleotide position is not well
conserved along the evolution, but a Watson–Crick (WC) base pair
at this position is present in 103 out of 106 mammal species and the
three species without a WC base pair at this position have developed
new WC base pairs in the anticodon stem [46]. Moreover, only three
mutations have been reported at nucleotides that interact with
positions where pathologic mutations in the mt-tRNAs have been
described [47]. These changes are likely pathologic mutations and the
m.606ANG/MT-TF mutation is one of them, interacting with the
m.618TNC/MT-TF associated with mitochondrial myopathy [48].
Despite the high rate of mutation [49], an mtDNA change is a rare
event. However, it is possible that environmental, nuclear or
mitochondrial genetic factors could increase the mutational rate
and give rise to more than one pathologic mutation in the same
mtDNA. Thus, a high level of natural radiation, such as that produced
in Kerala (India) [50], or allelic variants in nuclear genes involved in
mtDNA replication, could affect the mutational rate. In fact, patients
with thymidine phosphorylase deﬁciency [51] or with defects either
in the DNA helicase (Twinkle) or in the DNA polymerase γ (POLG)
show enhanced accumulation of mtDNA mutations [52]. Finally,
some mtDNA pathologic point mutations are associated with an
increase in ROS production, and, as previously mentioned, they are
mutagenic.
Then, is it possible to ﬁnd two or more pathologic mutations in
mtDNA? In fact this has already been observed on several occasions.
The mutations at positions m.11778GNA and m.14484TNC have been
found associated in LHON patients [53,54], the mutations at nucleo-
tide positions m.14484TNC and m.1555ANG have been found in
deafness-associated pedigree [55] and the m.5835GNA and
m.4315delA mutations in a CPEO patient [56]. Therefore, to ﬁnd the
best candidate for pathological mutation and to detect more than one
pathologic mutation, the entire mtDNA should be sequenced.
The complete sequence of the mtDNAwill also provide knowledge
about other mtDNA private variants that can act as modiﬁers of the
main mutation. A cybrid cell line containing more than 99% of the
m.3243ANG mutation in the MT-TL1 had a wild-type phenotype.
These cells were heteroplasmic for another mtDNA mutation,
m.12300GNA in the MT-TL2, which is apparently able to decode the
UUR leucine codons [57]. Ancient variants can also modify the
phenotypic effect of pathologic mutations, as frequently seen in the
association between mtDNA haplogroup J and the m.11778GNA and
m.14484TNC LHON mutations [24].
6. Absence of the candidate pathologic mutation in control
individuals
One of the ﬁrst criteria in considering the pathogenicity of a new
mutation is its presence in patients and absence in controls. A
pathologic mutation should not be found in normal individuals. But
how many controls must we check? For example, a new mutation
m.6489CNA was reported in the MT-CO1 gene in a patient suffering
from epilepsia partialis continua. This mutation was not checked in
controls, but it was not present at www.mitomap.org. The patient
also harbored a polymorphism at position m.7028CNT and a 9 bp
deletion m.8281-8289delCCCCCTCTA [58]. The same year 560 new
mtDNA sequences were reported and this mutation, along with the
other two mutations present in the patient, were found to deﬁne a
small cluster in the mitochondrial haplogroup T (sequences 72, 103,
148, 435 and 537 from [59,60]). Therefore, it is very likely that the
patient belongs to this cluster and the candidate pathologic
mutation is probably a population polymorphism [20]. There are
nowadays more than 3500 published mtDNA coding region
sequences [60] and it takes no more than a few minutes, at no
cost, to check all of them. Thus, we think that this is a good number
of sequences to start to rule out the absence of a new mutation in
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the COI subunit, the m.6955GNA, was noted in publication, and the
authors of the paper showed that it was not present in more than
4020 MT-CO1 sequences from patients and controls from all around
the world, or MITOMAP (www.mitomap.org) [61].
In any case, 3500 mtDNA sequences are only 0.000006% of the
whole humanpopulation and this ﬁrst test does not preclude the need
to check the mutation in the population from which the patient
comes, to rule out a geographically restricted population polymorph-
ism. Even though there is some homogeneity in geographic
frequencies and distribution, studies with large sample sizes and
better resolvedmtDNA trees have shown that clades of mtDNA exhibit
gradients [62] and these are more severe when more recent clusters
are considered. Thus, by having a haplogrouped control population
the number of required controls to be analyzed will decrease
considerably, because it will only be necessary to check the control
individuals that belong to the same mitochondrial cluster as the
patient to rule out a geographically restricted polymorphism.
Another important question to take into account is the quality of
the published sequences. As has often been noted [63], many reported
sequences have errors, and this opens the possibility of ﬁnding a
potentially pathologic mutation as part of one of those low quality
sequences. It is also very important to know whether the sequences
come from real control individuals or rather from the general
population that includes some patients. In general, the disease status
of the individuals contributing to these large data bases is often
unknown [43]. For example, the sequences mentioned above [59],
analyzed for a different purpose, were obtained from a general
population including normal controls and patients with type 2
diabetes or with neurodegenerative disorders (Alzheimer and
Parkinson diseases). Since some mutations in mtDNA are strongly
associated with syndromes in which diabetes is a prominent clinical
symptom [64], it is possible that some of the mutations found in these
‘control’ individuals were in fact pathologic.
Moreover, many mtDNA pathologic mutations have incomplete
penetrance and they require other factors to be expressed. For
example, the m.1494CNT mutation in the MT-RNR1 gene was found
in one individual (wh6980) from a population study [65]. However,
soon after this study, this mutation was deﬁned as causing
mitochondrial deafness [66]. Also, the mutations m.11778GNA and
m.14484TNC are frequently found in homoplasmy in normal females
of LHON pedigrees. If these individuals had been selected for
population studies, these mutations would now be considered
population polymorphisms. In fact, an individual carrying the
m.14484TNC but who had normal vision was identiﬁed during a
population screening [67].
When a new mtDNA mutation appears, a new branch is
established in the mitochondrial phylogenetic tree. Thus, the newest
mutations will be in the tips of the branches of the tree and those
surviving evolutionwill pass to deeper branches. However, pathologic
mutations will be removed by negative selection and they will not
remain in populations for a long time [28,30]. Therefore, a thorough
analysis of a large phylogeny, such as the one reported at www.
mitomap.org [60], can yield other clues, because it is not expected to
ﬁnd a very pathologic mutation in an ancient branch of the
phylogenetic tree. However, we need to be very careful in applying
this and other pathogenicity criteria since the m.11778GNA and
m.14484TNC LHON mutations and the m.1494CNT and m.1555ANG
deafness mutations have been reported at internal branches of the
phylogenetic tree [65,68–71].
The presence of a compensatory mutation would allow for the
discovery of another pathologic mutation in a normal population. For
example, a small cluster in the mitochondrial haplogroup A is deﬁned
by the pathologic mutation m.1494CNT [72]. This mutation gives rise
to a new base pair with the nucleotide at position 1555 andmakes the
mitochondrial ribosome more susceptible to aminoglycosides anddeafness. Thus, a pathologic mutation at m.1555ANG in this cluster
would obviate the base pair and the phenotypic effect.
7. Homoplasmy and heteroplasmy
All mtDNAs from an individual are usually identical; this condition
is called homoplasmy. When a new mutation appears, there will be
twomtDNA types, thewild-type and the newmutant; this condition is
called heteroplasmy. Heteroplasmy is taken as a good criterion for
assigning pathogenicity. Germinal cell lines go through a tight
bottleneck, thus reducing the number of mtDNAs that repopulate a
new individual [73]. Therefore, a new mutation in the germinal cell
line will reach homoplasmy in a few generations, or even in one [74].
The discovery of a heteroplasmic mutation, then, means that the
mutation is recent and probably will not be found as an ancient
polymorphism in the population. It is also commonly assumed that a
heteroplasmic mutation cannot achieve homoplasmy because in this
state it would be incompatible with life. However, heteroplasmy could
be a normal condition for any kind of mutation until it attains the
homoplasmic state.
The phenotypic effect will depend on themutational load: a higher
proportion of mutants will correlate with a more dramatic defect.
However, the phenotypic effect will also depend on the mitochondrial
energy needs of a particular tissue. This is known as the threshold
effect. Those tissues that are more dependent on mitochondrial
energy will have a lower threshold because a lower mutational load
will produce some phenotypic effects. However, this relationship
between the proportion of themtDNAmutation and phenotypic effect
will also depend on other factors, such as the mtDNA levels. For
example, it has been shown that segments of human skeletal muscle
ﬁbers harboring a pathogenic mtDNA mutation retain normal
cytochrome oxidase activity by maintaining a minimum amount of
wild-typemtDNA. The segment of themultinucleated cell responds by
non-selectively proliferating its entire mtDNA content, to restore
wild-type mtDNA to its optimal level [75].
It is normally assumed that 10–30% of wild-type mtDNA is
sufﬁcient to compensate for a mutation in a mitochondrial tRNA.
However, sometimes the presence of extremely low levels of a
pathologic mutation is associated with a mitochondrial disease. For
example, some patients with type II diabetes show very low levels of
the m.3243ANG mutation [76]. These percentages were found in
blood cells, and post-mitotic tissues usually have much higher levels
of the mutant mtDNA. However, there was also a report about a
patient with very low levels of the m.3243ANG mutation in blood
and lower levels in muscle [77]. Thus, a dominant effect must be
involved in the pathogenicity of this case. In this sense, the
m.5545CNT transition in the MT-TW at low levels of heteroplasmy—
below under 25%—caused a severe multisystem disorder and res-
piratory chain deﬁciency. The pathogenic threshold for the
mutation in cybrids in this case was between 4% and 8%, implying a
dominant mechanism. These ﬁndings pose new diagnostic challenges,
because such mutations may easily go undetected in normal tests
[78].
Singlemuscle ﬁber analysis correlates themutational loadwith the
staining pattern for the cytochrome oxidase activity of different single
muscle ﬁbers. Therefore, this test only can be performed for
heteroplasmic mutations that affect complex IV activity. A higher
proportion of the mutation will be associated with a lower COX
activity, thus directly relating the genotype with the phenotype.
However, the results are not always straightforward. For example, the
ancient polymorphism previously mentioned, m.6489CNA, and
therefore probably homoplasmic, was reported to be heteroplasmic
and with differing proportions of the mutation in different muscle
ﬁbers [58]. Furthermore, another homoplasmic mutation [43] was
also reported to be heteroplasmic and with different mutation loads
depending on the particular muscle ﬁber in question [42]. In both
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explain the heteroplasmy, but the difference in the proportion of the
mutation was not explained. It is quite possible that mtDNA
pseudogenes, integrated in the nuclear genome, are responsible for
this problem. In fact, it was reported some years ago that patients with
Alzheimer disease were heteroplasmic for several missensemutations
in the mtDNA genes. These mutations were also present at low levels
in normal individuals [79]. Immediately after these theoretically
important ﬁndings, two different research groups demonstrated that
the cause of this heteroplasmic state was ampliﬁcation of pseudogene
sequences, and it was very likely that the DNA extraction method
differentially enriched the samples in nuclear DNA depending on the
physiologic state of the cell [80–82]. There may be a similar
explanation for the anomalous results and for the previously noted
errors in individual muscle ﬁber analysis.
8. Conservation index and substitution type
The histidines 82, 96, 182 and 196 of the cytochrome b subunit of
complex III are conserved in 1121, 1122, 1123 and 1118 out of 1124
species, respectively, from protists to mammals. These histidines bind
the heme groups to fulﬁll the electron transfer reactions performed
by this protein, and likely their absence in some species is due to
sequencing errors. This example gives us the logic for one of the
pathogenicity criteria commonly used in the mitochondrial disease
ﬁeld, namely, functionally very important amino acids will be highly
conserved throughout evolution.
A high conservation index (CI) is a good clue for the functional
importance of a particular amino acid, but the contrary is not
necessarily true. The methionine at amino acid position 64 of the p.
MT-ND6 subunit is only conserved in 89 (12.6%) out of 817 species
from protists to mammals. However, the LHON m.14484TNC patho-
logic mutation affects this particular amino acid, p.MT-ND6:Met64Val.
Thus, a low CI does not directly rule out the potential pathogenicity of
a new mutation. Then why are some amino acids with a low CI
important? The Met64 at p.MT-ND6 appeared at the top of the
radiation of primates. The p.MT-ND6 subunit is part of respiratory
complex I and is located in the subcomplex Iα [83]. This complex
contains 45 other subunits, and it has recently been shown that some
mtDNA and nDNA-encoded complex I structural subunits, such as
NDUFA1, have evolved faster in primates [84]. NDUFA1 is located in
the subcomplex Iα-λ, as p.MT-ND6 [83]. Therefore, parallel co-
evolution may explain the low CI of Met64 at p.MT-ND6. In this
sense, xenomitochondrial cybrids with human nucleus and chimpan-
zee mitochondria show a complex I deﬁciency [85], thus highlighting
the importance of strong interaction between nDNA and mtDNA-
encoded structural subunits. In fact, it has been shown that the
mtDNA-encoded COX residues in close physical proximity to nDNA-
encoded COX residues evolve more rapidly than the other mitochon-
drial-encoded COX residues, and thus display an optimizing interac-
tion because the faster mtDNA mutation rate will allow sampling of
more residues in the interacting region by accommodating mutations
important for subunit interaction [86].
Compensatory mechanisms may also explain why population
polymorphisms can affect highly conserved amino acids. We have
already seen that the m.6489CNA, p.MT-CO1:Leu196Ile deﬁnes a
cluster in the mitochondrial haplogroup T. Leu196 is conserved in
1234 (94.4%) of 1307 species. This is an interesting issue to consider
since if a homoplasmic mutation is present in a particular pedigree, it
is possible that only the index case would develop the disease if he/
she also harbored a particular nuclear allele. It would also be possible
that the transfer of these mitochondria to a rho0 cell line without the
particular nuclear allele would not reproduce the pathologic pheno-
type. In these cases, the sequencing of the genes for those subunits
that interact with the one presenting the mutation could produce
interesting surprises.The conservation index is a good criterion when it is correctly
applied because the results will be dependent on the species analyzed.
Which species and how many of them should be considered? There
are now more than 1000 complete mtDNA sequences from different
species (www.mitomap.com). Why restrict ourselves to a small
number of species when we can select a large number of them, from
protists to humans? Relevant to this point, a new pathologic
substitution p.MT-CO1:Gly351Asp, m.6955GNA has recently been
described; it was conserved in 1302 (99.6%) of 1307 species from
protists to mammals [61]. Moreover, the CI of a candidate pathologic
mutation can be compared with that of other pathologic mutations
reported in the same mtDNA gene. Thus, the CI of the mutation
previously described is higher than that of the only other described p.
MT-CO1 pathologic missense mutations (m.6328CNT, p.MT-CO1:
Ser142Phe) [87] associated with a classical mitochondriopathy, in
1208 (92.4%) of 1307 species.
Another criterion used to deﬁne pathogenicity is the type of amino
acid substitution. In general, the existence of great differences in the
chemical properties of two amino acids increases the probability of
there being a pathologic substitution. However, every amino acid can
be classiﬁed in many different groups depending on its chemical
properties, although polarity and size are the most frequently used.
Thus, practically every substitution can be deﬁned as non-conserva-
tive, if a particular property is considered. Moreover, the phenotypic
effect of a severe substitution will also depend on the protein domain
affected. An analysis of a particular change in a particular protein in
the human phylogeny or in different species may yield some clues as
to the effect of this substitution. For example, a Gly to Asp replacement
has never been described in the human p.MT-CO1 but it has been
found several times in Saccharomyces cerevisiae and Rhodobacter
sphaeroides COX subunit I, and all of them are respiration-deﬁcient
mutants [61].
9. The deﬁnitive evidence: the transmitochondrial cell line
(cybrid)?
The previously mentioned criteria will give some evidence as to
the pathogenicity of a particular point mutation. However, functional
evidence is always needed if wewant to conﬁrm the pathogenicity of a
new mutation. In this sense, the transmitochondrial cell line model is
nowadays considered to provide the strongest evidence to deﬁne a
candidate mutation as pathologic. The transfer of a particular
phenotype by repopulating human cell lines emptied of their
mtDNA (ρ0-cells) with another mitochondrial background is very
good evidence of the pathogenicity of the particular mutated mtDNA
[88,89]. This technique has been used to determine the pathogenicity
of human mtDNA point mutations since 1991 [90], but the results are
not always straightforward.
As previously noted, m.14484TNC is an LHON-associated patho-
logical mutation. However, cybrids harboring this mutation did not
show a decrease in growth rate or in complex I activity [91], although
more recently a big decrease in the ATP levels has been reported [92].
Thus, it is very important to analyze the correct parameters to
demonstrate the pathogenicity of the mutation. Further, the
m.5703GNA/MT-TN mutation has been associated with a severe
mitochondrial protein synthesis defect and a reduction in steady-
state levels of tRNAAsn but several galactose-resistant clones with
restored OXPHOS function and higher levels of the mutant tRNA
were found. These cells contained homoplasmic levels of the
mutation and no other detectable alteration in the MT-TN gene.
Apparently, nuclear-encoded factors can compensate for the patho-
genic mutation [93]. Conﬁrming this fact, the homoplasmic point
mutation m.1624CNT/MT-TV caused a profound metabolic disorder
that resulted in the neonatal deaths of many siblings [94]. In
transmitochondrial cell lines established from the proband, the
marked respiratory deﬁciency was lost, and by inducing the
Table 3
Considerations for the pathogenicity criteria of mtDNA point mutation
⁎ The control population must be correctly deﬁned. A high number of geographically
and genetically matched controls are important.
⁎ Themutation should be found in the tips of themtDNA phylogenetic tree but potential
compensatory changes must be considered for mutations at internal branches of
the tree.
⁎ Thewhole mtDNA should be sequenced to rule out another better candidate mutation
or the existence of two pathologic mutations.
⁎ Dominant effects for mtDNA mutations must be considered.
⁎ It is important to considerer interaction between nucleotides or amino acids.
⁎ The function of many mtDNA-encoded subunits or protein domains is still unknown.
⁎ Cybrids are good models but they are not free of problems.
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cybrids, the steady-state levels of the mutated mt-tRNAVal were
partially restored [95].
MtDNA-encoded factors can also compensate for pathogenic
mutations. Thus, it has been reported that cybrids with 99% of the
m.3243ANG/MT-TL1 mutation were phenotypically wild-type,
because they contained 10% of a suppressor mutation m.12300GNA/
MT-TL2. This anticodon mutation generates a MT-TL2 able to decode
UUR leucine codons. Very importantly, the proportion of the mutant
sequence was barely detectable by direct sequencing of the PCR
product [57].
Most mtDNAmutations are recessive and they have to reach a high
percentage in a speciﬁc tissue or cell line before producing a
phenotype. However, it has recently been reported that the patho-
genic threshold for the m.5545CNT/MT-TW mutation in cybrids is
between 4% and 8%, implying a dominant mechanism of action, again
barely detectable by direct sequencing [78].
In all these examples, the cybrid model would have given negative
results and only prior knowledge that the mutations were pathologic
allowed the search for other parameters or compensatory mechan-
isms. However, the cybrid model requires some precautions, as wisely
noted by Swerdlow [96]. A pathologic mutation m.13528ANG in the
MT-ND5 gene in a MELAS patient has recently been reported.
Measurements of oxygen consumption with complex I substrates in
cybrids revealed a complex I deﬁciency [97]. However, the complex I
activity on muscle homogenate was normal and the mutation had
been previously found at internal branches of the mtDNA phyloge-
netic tree [60]. The number of culture passages or the mtDNA levels of
these cybrids was not reported [97]. Therefore it is possible that these
cells had not recovered, after the cybridization, the normal mtDNA
levels for that particular growth conditions; as it is well known,
mitochondrial function is very much dependent on the mtDNA levels
in cultured cells [98].
10. Conclusion
Although pathogenicity criteria are very useful tools to demon-
strate whether a newly found point mutation in mtDNA is pathogenic,
as we have seen there are many examples in the literature that do not
in fact fulﬁll all of them. Therefore, this is not a rare situation; the ﬁeld
of mitochondrial pathology is very complex and one cannot be too
strict in the application of these criteria (Table 3).
In 2000, Salvatore DiMauro, talking about mtDNA pathologic
mutations, wondered whether we were scraping the bottom of the
barrel [99]. His answer was a resounding ‘no’. Many of the latest
ﬁndings lead us to reformulate the question: Are we still scraping the
top of the barrel? It is likely that many new mtDNA mutations remain
to be found, that some population polymorphisms will be associated
with diseases in particular circumstances, and that some pathologic
mutations will be found in normal individuals. The reason for this is
that mtDNA-encoded proteins are only a part of the mitochondrial
proteome and its interactionwith the other nuclear-encoded proteins,will determine the pathological state of the individuals [100].
Furthermore, very little is known about the role of mtDNA mutations
in age-linked diseases. These are considered multifactorial disorders,
with genetic and environmental factors involved. The phenotypic
effect of these variants will be more moderate and their need to
interact with other factors to produce the pathological phenotype will
render the classic cybrid model an extremely simplistic approach.
Other more elaborate approaches will be required, for example by
considering possible compensatory mechanisms [101].
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